Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

This publication has 17 references indexed in Scilit:

• Evidence for a viral superantigen in humans
  Nature, 1992
• Vaccination of Vaccinia-Naive Adults with Human Immunodeficiency Virus Type 1 gp160 Recombinant Vaccinia Virus in a Blinded, Controlled, Randomized Clinical Trial
  The Journal of Infectious Diseases, 1992
• Immunisation with canarypox virus expressing rabies glycoprotein
  The Lancet, 1992
• Rabies-specific production of interleukin-2 by peripheral blood lymphocytes from human rabies vaccinees
  Vaccine, 1991
• Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus
  Vaccine, 1991
• The A/Mallard/67S0/78 Avian-Human, but Not the A/Ann Arbor/6/60 Cold-Adapted, Influenza A/Kawasaki/86 (H1N1) Reassortant Virus Vaccine Retains Partial Virulence for Infants and Children
  The Journal of Infectious Diseases, 1991
• Efficacy studies on a canarypox-rabies recombinant virus
  Vaccine, 1991
• Fowlpox virus as a vector in non-avian species
  Vaccine, 1988
• Expression of rabies virus glycoprotein from a recombinant vaccinia virus
  Nature, 1984
• Immune Responses of Humans to a Human Diploid Cell Strain of Rabies Virus Vaccine: Lymphocyte Transformation, Production of Virus-Neutralizing Antibody, and Induction of Interferon
  The Journal of Infectious Diseases, 1979